Rachael Cella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rachael Cella has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Luo
Department of Psychiatry, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA
1 shared publication - Bushra Alfakhri
Department of Psychiatry, Eastern Connecticut Health Network, 71 Haynes Street, Manchester, CT 06040, USA
1 shared publication David C. Steffens
Department of Psychiatry, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, 06030, United States
1 shared publicationGodfrey D. Pearlson
Olin Neuropsychiatry Research Center, Institute of Living, 200 Retreat Avenue, Hartford, CT, 06106, United States; Departments of Psychiatry and Neuroscience, Yale University School of Medicine, New Haven, CT, 06511, United States
1 shared publication- Gualberto Ruaño
Institute of Living at Hartford Hospital Hartford Connecticut USA
1 shared publication - Helen Bian
University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030, USA
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (10) , 1554
Historical Perspective and Clinical Implementation of Pharmacogenomics (PGx) Technology with Clinical Decision Support (CDS) in Child and Adolescent Psychiatry
Pharmacogenomics (PGx) uses the variation in a patient’s genetic profile to assist with medication choice, with the goal of shortening the trial-and-error process of prescribing in psychiatry. Over the past few decades, PGx technology has evolved greatly to identify various genetic polymorphisms in drug-metabolizing enzymes; however, clinical use and relevance of PGx in child and adolescent psychiatry (CAAP) remain limited. This narrative review explores the historical evolution of PGx, compares key technological advancements, and evaluates their clinical relevance to CAAP. We address current barriers to PGx implementation, including developmental differences in pharmacokinetics between adults and children, the lack of robust evidence of clinical efficacy in youth populations, and inconsistent guidelines causing clinician confusion. We also highlight the need for clinical decision support (CDS) tools and broader practical and ethical considerations before widespread uptake of PGx would be feasible.
- 1 October 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (10) , 1554
Open AccessHistorical Perspective and Clinical Implementation of Pharmacogenomics (PGx) Technology with Clinical Decision Support (CDS) in Child and Adolescent Psychiatry
Pharmacogenomics (PGx) uses the variation in a patient’s genetic profile to assist with medication choice, with the goal of shortening the trial-and-error process of prescribing in psychiatry. Over the past few decades, PGx technology has evolved greatly to identify various genetic polymorphisms in drug-metabolizing enzymes; however, clinical use and relevance of PGx in child and adolescent psychiatry (CAAP) remain limited. This narrative review explores the historical evolution of PGx, compares key technological advancements, and evaluates their clinical relevance to CAAP. We address current barriers to PGx implementation, including developmental differences in pharmacokinetics between adults and children, the lack of robust evidence of clinical efficacy in youth populations, and inconsistent guidelines causing clinician confusion. We also highlight the need for clinical decision support (CDS) tools and broader practical and ethical considerations before widespread uptake of PGx would be feasible.